United States · FDA National Drug Code directory
XIFAXAN
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 65649-303_b2e9bb84-e97e-4e7e-8a23-425418b4374d
- Product NDC
- 65649-303
- Form
- TABLET
- Composition / generic term
- rifaximin
- Labeler
- Salix Pharmaceuticals, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20100501
- Source listing expiry
- 20271231
Source-listed ingredients
- RIFAXIMIN — 550 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 3 CARTON in 1 TRAY (65649-303-01) / 1 BLISTER PACK in 1 CARTON / 2 TABLET in 1 BLISTER PACK · 65649-303-01
- 60 TABLET in 1 BOTTLE (65649-303-02) · 65649-303-02
- 6 BLISTER PACK in 1 CARTON (65649-303-03) / 10 TABLET in 1 BLISTER PACK · 65649-303-03
- 3 CARTON in 1 TRAY (65649-303-05) / 1 BLISTER PACK in 1 CARTON / 3 TABLET in 1 BLISTER PACK · 65649-303-05
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →